AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do.
We are at the heart of oncology R&D in the UK and are committed to advancing the science of oncology to deliver life-changing medicines. Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations and ensure that these reach people in most need.
GB-37921 July 2022